135 related articles for article (PubMed ID: 35902275)
1. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.
Jalal SI; Guo A; Ahmed S; Kelley MJ
Semin Oncol; 2022 Jul; ():. PubMed ID: 35902275
[TBL] [Abstract][Full Text] [Related]
2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
3. Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.
Vashistha V; Armstrong J; Winski D; Poonnen PJ; Hintze B; Price M; Snowdon JL; Weeraratne D; Brotman D; Jackson GP; Kelley MJ
JCO Oncol Pract; 2021 Jul; 17(7):e1012-e1020. PubMed ID: 33780286
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
7. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
8. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
Kuang X; Xiao J; Dai LX; Zhang LH; He BX
Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
10. The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R; Kamireddy AP; Hussaini SM; Chatterjee S; Hasan Q; Jain J
Front Genet; 2023; 14():1256756. PubMed ID: 38155717
[TBL] [Abstract][Full Text] [Related]
11. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; JÓ“nne PA; Gusev A; Kwiatkowski DJ
Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
13. Genomic Landscape of NSCLC in the Republic of Ireland.
Keogh RJ; Barr MP; Keogh A; McMahon D; O'Brien C; Finn SP; Naidoo J
JTO Clin Res Rep; 2024 Feb; 5(2):100627. PubMed ID: 38333230
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
15. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
16. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
17. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
Front Oncol; 2021; 11():750657. PubMed ID: 34926258
[TBL] [Abstract][Full Text] [Related]
19. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Stein MK; Oluoha O; Patel K; VanderWalde A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]